Cargando…
A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
Overdiagnosis of breast cancer, defined as diagnosing a cancer that would otherwise not cause symptoms or death in a patient's lifetime, costs U.S. health care system over $1.2 billion annually. Overdiagnosis rates, estimated to be around 10%–40%, may be reduced if indolent breast findings can...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313854/ https://www.ncbi.nlm.nih.gov/pubmed/35915601 http://dx.doi.org/10.1111/poms.13691 |
_version_ | 1784754176182452224 |
---|---|
author | Tunç, Sait Alagoz, Oguzhan Burnside, Elizabeth S. |
author_facet | Tunç, Sait Alagoz, Oguzhan Burnside, Elizabeth S. |
author_sort | Tunç, Sait |
collection | PubMed |
description | Overdiagnosis of breast cancer, defined as diagnosing a cancer that would otherwise not cause symptoms or death in a patient's lifetime, costs U.S. health care system over $1.2 billion annually. Overdiagnosis rates, estimated to be around 10%–40%, may be reduced if indolent breast findings can be identified and followed with noninvasive imaging rather than biopsy. However, there are no validated guidelines for radiologists to decide when to choose imaging options recognizing cancer grades and types. The aim of this study is to optimize breast cancer diagnostic decisions based on cancer types using a large‐scale finite‐horizon Markov decision process (MDP) model with 4.6 million states to help reduce overdiagnosis. We prove the optimality of a divide‐and‐search algorithm that relies on tight upper bounds on the optimal decision thresholds to find an exact optimal solution. We project the high‐dimensional MDP onto two lower dimensional MDPs and obtain feasible upper bounds on the optimal decision thresholds. We use real data from two private mammography databases and demonstrate our model performance through a previously validated simulation model that has been used by the policy makers to set the national screening guidelines in the United States. We find that a decision‐analytical framework optimizing diagnostic decisions while accounting for breast cancer types has a strong potential to improve the quality of life and alleviate the immense costs of overdiagnosis. Our model leads to a [Formula: see text] reduction in overdiagnosis on the screening population, which translates into an annual savings of approximately $300 million for the U.S. health care system. |
format | Online Article Text |
id | pubmed-9313854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93138542022-07-30 A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis Tunç, Sait Alagoz, Oguzhan Burnside, Elizabeth S. Prod Oper Manag Original Articles Overdiagnosis of breast cancer, defined as diagnosing a cancer that would otherwise not cause symptoms or death in a patient's lifetime, costs U.S. health care system over $1.2 billion annually. Overdiagnosis rates, estimated to be around 10%–40%, may be reduced if indolent breast findings can be identified and followed with noninvasive imaging rather than biopsy. However, there are no validated guidelines for radiologists to decide when to choose imaging options recognizing cancer grades and types. The aim of this study is to optimize breast cancer diagnostic decisions based on cancer types using a large‐scale finite‐horizon Markov decision process (MDP) model with 4.6 million states to help reduce overdiagnosis. We prove the optimality of a divide‐and‐search algorithm that relies on tight upper bounds on the optimal decision thresholds to find an exact optimal solution. We project the high‐dimensional MDP onto two lower dimensional MDPs and obtain feasible upper bounds on the optimal decision thresholds. We use real data from two private mammography databases and demonstrate our model performance through a previously validated simulation model that has been used by the policy makers to set the national screening guidelines in the United States. We find that a decision‐analytical framework optimizing diagnostic decisions while accounting for breast cancer types has a strong potential to improve the quality of life and alleviate the immense costs of overdiagnosis. Our model leads to a [Formula: see text] reduction in overdiagnosis on the screening population, which translates into an annual savings of approximately $300 million for the U.S. health care system. John Wiley and Sons Inc. 2022-03-08 2022-05 /pmc/articles/PMC9313854/ /pubmed/35915601 http://dx.doi.org/10.1111/poms.13691 Text en © 2022 The Authors. Production and Operations Management published by Wiley Periodicals LLC on behalf of Production and Operations Management Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Tunç, Sait Alagoz, Oguzhan Burnside, Elizabeth S. A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis |
title | A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis |
title_full | A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis |
title_fullStr | A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis |
title_full_unstemmed | A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis |
title_short | A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis |
title_sort | new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313854/ https://www.ncbi.nlm.nih.gov/pubmed/35915601 http://dx.doi.org/10.1111/poms.13691 |
work_keys_str_mv | AT tuncsait anewperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis AT alagozoguzhan anewperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis AT burnsideelizabeths anewperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis AT tuncsait newperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis AT alagozoguzhan newperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis AT burnsideelizabeths newperspectiveonbreastcancerdiagnosticguidelinestoreduceoverdiagnosis |